Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22666367)

1.

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F.

PLoS One. 2012;7(5):e37563. doi: 10.1371/journal.pone.0037563. Epub 2012 May 30.

2.

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K.

Cancer Sci. 2008 Jan;99(1):159-65. Epub 2007 Oct 22.

PMID:
17953709
3.

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.

J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.

4.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.

J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6.

PMID:
19247201
5.

Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.

Lee SJ, Lee J, Park SH, Park JO, Park YS, Kang WK, Lee J, Yim DS, Lim HY.

Invest New Drugs. 2012 Aug;30(4):1540-7. doi: 10.1007/s10637-011-9706-5. Epub 2011 Jun 22.

PMID:
21695438
6.
7.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
8.

Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.

Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P.

Aliment Pharmacol Ther. 2011 Nov;34(10):1193-201. doi: 10.1111/j.1365-2036.2011.04860.x. Epub 2011 Sep 29.

PMID:
21958438
9.

Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.

Kim JW, Lee JO, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.

Am J Clin Oncol. 2011 Apr;34(2):125-9. doi: 10.1097/COC.0b013e3181d31ed2.

PMID:
20308869
10.

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.

Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ.

Cancer Chemother Pharmacol. 2011 Aug;68(2):539-45. doi: 10.1007/s00280-011-1671-3. Epub 2011 May 19.

PMID:
21594722
11.

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.

Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Königsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M.

Oncologist. 2009 Jan;14(1):70-6. doi: 10.1634/theoncologist.2008-0191. Epub 2009 Jan 14.

12.

Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.

Woo HY, Heo J, Yoon KT, Kim GH, Kang DH, Song GA, Cho M.

Scand J Gastroenterol. 2012 Jul;47(7):809-19. doi: 10.3109/00365521.2012.683040. Epub 2012 May 8.

PMID:
22563643
13.

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.

Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T.

Cancer. 2012 Nov 1;118(21):5293-301. doi: 10.1002/cncr.27543. Epub 2012 Apr 19.

14.

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.

Boudou-Rouquette P, Ropert S, Mir O, Coriat R, Billemont B, Tod M, Cabanes L, Franck N, Blanchet B, Goldwasser F.

Oncologist. 2012;17(9):1204-12. Epub 2012 Jul 2.

15.

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G.

Oncologist. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5.

16.

[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].

Xu L, Li P, Lin XJ, Yuan YF, Zhang YQ, Chen MS.

Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):58-61. Chinese.

PMID:
19538872
17.

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R.

Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Review.

18.

[The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].

Amano R, Yamada N, Noda E, Kubo N, Tanaka H, Muguruma K, Takashima T, Yashiro M, Maeda K, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2676-8. Japanese.

PMID:
21224677
19.

Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.

Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B.

Invest New Drugs. 2011 Dec;29(6):1511-4. doi: 10.1007/s10637-010-9514-3. Epub 2010 Aug 13.

PMID:
20706860
20.

Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?

Sacco R, Bargellini I, Ginanni B, Bertini M, Faggioni L, Federici G, Romano A, Bertoni M, Metrangolo S, Altomare E, Parisi G, Tumino E, Scaramuzzino A, Bresci G, Bartolozzi C.

Expert Rev Anticancer Ther. 2012 Jul;12(7):869-75. doi: 10.1586/era.12.58.

PMID:
22845401
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk